Hydration with 0.9% NS at 80 mL/hour will be administered for at least 7 days. Appropriate amount of KCl should be mixed.

GVHD prophylaxis will include cyclosporine A (CSA) and methotrexate.

Eligibility

Ages Eligible for Study:

15 Years to 65 Years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Patients must be 15 years of age or older and 65 years of age or younger

Patients with CLL, lymphoma, or multiple myeloma will be included in this study

No prior anti-cancer treatment should be done within 30 days.

Informed consent should be given.

Patients should have an HLA-identical or single HLA-locus mismatched donor.

Karnofsky performance scale should be 50 or over (see Appendix I).

Exclusion Criteria:

Patients must not have a psychiatric disorder or mental deficiency severe as to make compliance with the stem cell transplant treatment unlike, and making informed consent impossible.

Patients with high serum creatinine level will be excluded.

Patients should have uncontrolled infection.

No major anticipated illness or organ failure incompatible with survival from stem cell transplant.

Serum bilirubin less than or equal to 4.0 mg/dL.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00772811